Why the study?
What are the predictors of warfarin time in therapeutic range in patients with a continuous-flow left ventricular assist device?
Population
121 ambulatory patients implanted with a continuous-flow left ventricular assist device (CF-LVAD)
Design
Cohort
Follow-up
12 months
Key result
In CF-LVAD recipients, female sex (-10.1%, p=0.04), type 2 diabetes (-11.5%, p=0.006), and prior warfarin use (-8.3%, p=0.03) independently predicted lower time in therapeutic range.
Authors
Loading...
May warrant closer INR monitoring in at-risk CF-LVAD patients; hypothesis-generating and should not yet change practice.
Observational (n=121)
No
What are the predictors of warfarin time in therapeutic range in patients with a continuous-flow left ventricular assist device?
In CF-LVAD patients, female sex, type 2 diabetes, and prior warfarin use predict lower time in therapeutic range, identifying high-risk subgroups for suboptimal anticoagulation.
Henderson et al. (2019) conducted an observational in Continuous-flow left ventricular assist device (CF-LVAD) requiring anticoagulation (n=121). Patient characteristics and clinical risk factors was evaluated on Time in therapeutic range (TTR). In CF-LVAD recipients, female sex (-10.1%, p=0.04), type 2 diabetes (-11.5%, p=0.006), and prior warfarin use (-8.3%, p=0.03) independently predicted lower time in therapeutic range.